Fibril-mediated adherence of Actinomyces viscosus to saliva-treated hydroxyapatite.
Wheeler, T T
Fibril-mediated adherence of Actinomyces viscosus strain T14V cells to saliva-treated hydroxyapatite was studied. Fibrils were purified by ammonium sulfate precipitation and differential centrifugation from the crude supernatant of whole cells that were sheared by one passage through a French pressure cell. Purified fibrils and crude supernatant inhibited strain T14V adherence to saliva-treated hydroxyapatite to similar extents. However, anti-strain T14V serum and antifibril specific antibody completely abolished strain T14V adherence. The blocking immunoglobulin could be adsorbed from anti-T14V serum by strain T14V whole cells, by purified fibrils, and, to a lesser extent, by cell walls. It was concluded that fibrils mediate adherence of strain T14V cells to saliva-treated hydroxyapatite. In addition, fibril preparations were shown to contain more than 95% protein and to be antigenically homogeneous by immunodiffusion and Laurell rocket immunoelectrophoresis. Purified fibril preparations showed serological identity with the virulence-associated 1 antigen of Lancefield-extracted T14V cells, whereas crude supernatants contained both virulence-associated 1 and virulence-associated 2 antigens, as shown by rocket immunoelectrophoresis.
ACESSO AO ARTIGOhttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=550973
- Relative hydrophobicities of Actinomyces viscosus and Actinomyces naeslundii strains and their adsorption to saliva-treated hydroxyapatite.
- Influence of Growth Medium on Adsorption of Streptococcus mutans, Actinomyces viscosus, and Actinomyces naeslundii to Saliva-Treated Hydroxyapatite Surfaces
- Differences in the Adsorptive Behavior of Human Strains of Actinomyces viscosus and Actinomyces naeslundii to Saliva-Treated Hydroxyapatite Surfaces
- Influence of Sublethal Antibiotic Concentrations on Bacterial Adherence to Saliva-Treated Hydroxyapatite
- Specific inhibition of adsorption of Actinomyces viscosus T14V to saliva-treated hydroxyapatite by antibody against type 1 fimbriae.